الفهرس 
FingolimodOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
FTY720 is a novel SIP analogue and immunomodulatory agent, and currently approved for MS treatment. When administered it is phosphorylated in vivo, and the phosphorylated form induces numerous protective effects. The present work was performed to evaluate the potential role of the FTY-720, in rat I/R induced renal injury and its possible underlying renal protective mechanisms. Thirty male albino rats were used in this study and divided into three equal groups (ten rats each). group I; Sham operated control group: The rats were injected with saline at a dose of 10 ml/kg, IP as a vehicle, after laparotomy. group II; Ischemia / reperfusion group (I/R group): The rats were underwent renal I/R-injury and received vehicle. group III; FTY720 treated ischemia / reperfusion group (FTY720 treated I/R group): The rats were received single FTY720 injection at a dose of 1 mg/kg, I.P. immediately following renal I/R injury. After 24 hours, all rats were decapitated, blood samples were collected and kidneys were dissected. The following parameters were assayed: 1. Blood Urea. 2. Serum Creatinine. 3. Serum Total Antioxidant Capacity.